Novartis posts all-time high on raised outlook

Bloomberg

Novartis AG, the Swiss drugmaker, raised its earnings outlook for the second time this year, buoyed by key heart and psoriasis medicines.
Earnings excluding some items are expected to increase by a low double-digit to mid-teens percentage, the Basel, Switzerland-based company said. Novartis previously forecast a high single-digit percentage increase. The outlook for sales, new medicines and the Sandoz generics unit were also raised.
Investors are looking for early signs of how the company’s $2.1 million gene therapy Zolgensma — approved in the US in May — is faring in its initial months.